CHRS · Coherus Oncology, Inc. · Executive Compensation
Market Cap
$213.98M
Shares
154.50M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Dennis Lanfear | President, Chief Executive Office and Chairman of the Board of Directors | $5,361,707 |
| Darlene P. Horton | former Chief Medical and Regulatory Affairs Officer | $3,629,789 |
| Jean-Frédéric Viret | Chief Financial Officer | $1,829,591 |
| Vincent Anicetti | Chief Operating Officer | $1,810,841 |
| Vladimir Vexler | Chief Scientific Officer | $1,757,229 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Vincent Anicetti | Chief Operating Officer | $1,818,680 |
| Vladimir Vexler | Chief Scientific Officer | $1,355,163 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Michael Ryan | Class II director | Appointed | 2025-04-25 |
| Rita A. Karachun | Class II director | Resigned | 2025-04-25 |
| Rita A. Karachun | Class I director | Appointed | 2025-04-25 |
| Michael Ryan | Class III director | Resigned | 2025-04-25 |
| Paul Reider | Chief Commercial Officer | Resigned | 2025-04-22 |
Key facts
CIK
1512762
CUSIP
19249H103
13F (30d)
96 filings
96 filers
Visit website
Investor relations